Aura Biosciences, Inc. (AURA)

6,93 -0,12 (-1,70%) Alla chiusura: 04:00PM EDT

Aura Biosciences, Inc.

80 Guest Street
5th Floor
Boston, MA 02135
United States
617 500 8864
https://www.aurabiosciences.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 88

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Elisabet de los Pinos Ph.D.	Founder, CEO, President & Director	895,16k	N/D	1974
Ms. Julie B. Feder	Chief Financial Officer	604,2k	N/D	1971
Dr. Mark Plavsic D.V.M., Ph.D.	Chief Technology Officer	N/D	N/D	1961
Mr. Conor Kilroy	General Counsel & Secretary	N/D	N/D	1982
Mr. Patrick Nealon	Senior Vice President of Clinical Development Operations	N/D	N/D	N/D
Dr. Bruce Brown M.D.	Senior VP & Therapeutic Area Head of Urologic Oncology	N/D	N/D	N/D
Dr. Anthony Daniels M.D.	Therapeutic Area Head of Ocular Oncology	N/D	N/D	N/D
Dr. Richard Mountfield Ph.D.	Senior Vice President of Regulatory Affairs & Quality	N/D	N/D	N/D
Dr. Jill J. Hopkins M.D.	Chief Medical Officer & President of Research and Development	N/D	N/D	1965

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmette–guérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Aura Biosciences, Inc. al 1 giugno 2024 è 7. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 5; diritti degli azionisti: 8; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.